These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33764161)

  • 21. A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.
    Muraki M; Kunita Y; Shirahase K; Yamazaki R; Hanada S; Sawaguchi H; Tohda Y
    BMC Pulm Med; 2021 Jan; 21(1):26. PubMed ID: 33441146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities.
    Kalhan R; Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; MacKnight SD; Hahn B
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1149-1161. PubMed ID: 33911860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
    Albertson TE; Bowman WS; Harper RW; Godbout RM; Murin S
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1251-1265. PubMed ID: 31239659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
    Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
    Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
    Hsieh MJ; Chen NH; Cheng SL; Tao CW; Wei YF; Wu YK; Chan MC; Liu SF; Hsu WH; Yang TM; Lin MS; Liu CL; Kuo PH; Tsai YH
    Int J Chron Obstruct Pulmon Dis; 2022; 17():967-976. PubMed ID: 35510163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes.
    Mannino D; DiRocco K; Germain G; Laliberté F; Noorduyn SG; Urosevic A; Paczkowski R
    Adv Ther; 2024 Dec; 41(12):4557-4580. PubMed ID: 39453592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease.
    Gong Y; Lin C; Jin Y; Chen R
    Can Respir J; 2022; 2022():2878648. PubMed ID: 36060827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
    Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
    Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
    Rhee CK; Yoshisue H; Lad R
    Adv Ther; 2019 Mar; 36(3):495-519. PubMed ID: 30742242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
    Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
    Kalberg C; O'Dell D; Galkin D; Newlands A; Fahy WA
    Drugs R D; 2016 Jun; 16(2):217-27. PubMed ID: 27028749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
    McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
    Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world characteristics of patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy in Japan.
    Oga T; Mita C; Ito R; Requena G; Rothnie KJ; Noorduyn SG; Yuanita L; Yarita M
    Respir Investig; 2024 Jul; 62(4):685-694. PubMed ID: 38796907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
    Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
    Bogart M; Bengtson LGS; Johnson MG; Bunner SH; Gronroos NN; DiRocco KK
    Int J Chron Obstruct Pulmon Dis; 2024; 19():97-110. PubMed ID: 38226396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
    Singh D; Maleki-Yazdi MR; Tombs L; Iqbal A; Fahy WA; Naya I
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1413-24. PubMed ID: 27445468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
    Siler TM; Donald AC; O'Dell D; Church A; Fahy WA
    Int J Chron Obstruct Pulmon Dis; 2016; 11():971-9. PubMed ID: 27274218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice.
    Ding B; Kallenbach L; Slipski L; Wilk A; O'Brien D; Guranlioglu D
    Int J Chron Obstruct Pulmon Dis; 2020; 15():775-786. PubMed ID: 32346288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients.
    Miravitlles M; Gáldiz JB; Huerta A; Villacampa A; Carcedo D; Garcia-Rio F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():123-32. PubMed ID: 26848262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease.
    Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; MacKnight SD; Hahn B
    Pulm Ther; 2021 Jun; 7(1):203-219. PubMed ID: 33728597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.